![Page 1: Beaver Dam Eye Study: Overall Participant Flow](https://reader035.vdocuments.us/reader035/viewer/2022071807/56813022550346895d95a447/html5/thumbnails/1.jpg)
Beaver Dam Eye Study: Overall Participant Flow
Barbara E. K. Klein, et al. JAMA 2006;295:2752-2758
![Page 2: Beaver Dam Eye Study: Overall Participant Flow](https://reader035.vdocuments.us/reader035/viewer/2022071807/56813022550346895d95a447/html5/thumbnails/2.jpg)
Beaver Dam Eye Study: Flow of Participants From the Third Examination Who Were Eligible for
Nuclear Cataract Analyses
Barbara E. K. Klein, et al. JAMA 2006;295:2752-2758
![Page 3: Beaver Dam Eye Study: Overall Participant Flow](https://reader035.vdocuments.us/reader035/viewer/2022071807/56813022550346895d95a447/html5/thumbnails/3.jpg)
Distribution and Age-Adjusted ORs for Each Cataract Type Based on Statin Use
Barbara E. K. Klein, et al. JAMA 2006;295:2752-2758
![Page 4: Beaver Dam Eye Study: Overall Participant Flow](https://reader035.vdocuments.us/reader035/viewer/2022071807/56813022550346895d95a447/html5/thumbnails/4.jpg)
Characteristics at the Third Examination (1998-2000) of Participants
Who Developed Nuclear Cataract Compared With Those Who Did Not*
Barbara E. K. Klein, et al. JAMA 2006;295:2752-2758
![Page 5: Beaver Dam Eye Study: Overall Participant Flow](https://reader035.vdocuments.us/reader035/viewer/2022071807/56813022550346895d95a447/html5/thumbnails/5.jpg)
Five-Year Incidence of Nuclear Cataract Identified at Fourth Examination, Classified
by Use of Statins at Third Examination, 1998-
2000
Barbara E. K. Klein, et al. JAMA 2006;295:2752-2758
![Page 6: Beaver Dam Eye Study: Overall Participant Flow](https://reader035.vdocuments.us/reader035/viewer/2022071807/56813022550346895d95a447/html5/thumbnails/6.jpg)
Incident Nuclear Cataract by Duration of Statin Use*
Barbara E. K. Klein, et al. JAMA 2006;295:2752-2758